Nerissa C. Kreher
Independent DirectorDr. Nerissa C. Kreher, M.D. M.S. M.B.A., serves as Independent Director at Rezolute, Inc. since March 02, 2021. She serves as Director since July 1, 2026 at Xeris Biopharma Holdings, Inc. She served as Chief Medical Officer of Lucy Therapeutics, Inc. since 2024 until 2025. Dr. Kreher had been Chief Medical Officer of Entrada Therapeutics, Inc. since December 2020 until 2024. Dr. Kreher served as Senior Advisor at AVROBIO Inc. since December 17, 2018 until March 31, 2019 and served as its Chief Medical Officer from October, 2016 to December 2018. Dr. Kreher served as Global Head of Medical Affairs at Zafgen, Inc. since May 2015. She is Chief Medical Officer of Alltrna, Inc. from January 2025. Dr. Kreher is a Physician and Board Certified Pediatric Endocrinologist with deep academic, clinical research and biotechnology industry experience that includes both Medical Affairs and Clinical Development in start-up environments and within large biotechnology companies. Dr. Kreher has served as Chief Medical Officer of Entrada Therapeutics, Inc. since December 2020. From February 2019 to October 2020, Dr. Kreher served as Chief Medical Officer at Tiburio Therapeutics, Inc. where she was responsible for clinical development, clinical operations, regulatory and patient advocacy. She served as Global Clinical Development Lead for Neonatology at Shire. She served several roles at Alexion Pharmaceuticals and Enobia Pharma, where she became the Executive Medical Director, Medical Affairs Franchise Lead, Metabolic Diseases and was responsible for the global medical affairs metabolic disease program. Prior to that, she served as Medical Director of Medical Affairs at Genzyme, responsible for U.S. Medical Affairs for Endocrinology. She began her career in the industry as Director of U.S. Medical Affairs for Endocrinology at EMD Serono. From October 2016 to December 2018, Dr. Kreher served as Chief Medical Officer of Avrobio, Inc. where she oversaw clinical and regulatory development strategy for the company’s rare disease, ex vivo lentiviral gene therapy pipeline programs. From March 2015 to July 2016, Dr. Kreher served as Global Head (VP) of Clinical and Medical Affairs of Zafgen, Inc. where she was a strategic leader of a cross-functional team charged with creation of global development strategy for beloranib. Dr. Kreher is a board-certified pediatric endocrinologist. She is a Member of several professional organizations, including the Endocrine Society and the recipient of a number of awards and honors. Dr. Kreher received a B.S. degree in biology from the University of North Carolina, Chapel Hill from 1990 to 1994 ; her M.D. from East Carolina University School of Medicine from 1994 to 1998 ; her M.S. in Clinical Research from Indiana University-Purdue University Indianapolis, from 2002 to 2004 and an Executive M.B.A. from Northeastern University Graduate School of Business Administration from 2009 to 2010.
Positions
- Company NameRezolute, Inc.Stock CodeRZLTPositionIndependent DirectorColleagues
- NCNevan Charles ElamFounder, CEO & Acting Chairman of the Board
- DGDaron G. EvansChief Financial & Business Officer
- BKBrian Kenneth RobertsChief Medical Officer
- SKSunil KarnawatChief Commercial Officer
- MRMichael R. DeperroSenior VP & Head of Operations
- GMGilbert M. LabrucherieIndependent Director
- WHWladimir HogenhuisIndependent Director
- JMJerrold M. OlefskyMember of the Scientific Advisory Board
